The effective shelf creates immediate dilution risk. Monitor for ATM takedowns and any pricing announcements. The unresolved clinical hold adds binary risk — positive resolution could offset some dilution concerns, but the capital raise signal is clear. Consider positioning for continued weakness until the company provides clarity on clinical hold resolution and capital deployment plans.
Price Chart
Executive Summary
PepGen's S-3 shelf registration (File No. 333-296016) became effective on May 21, 2026, enabling the company to sell up to $400M in securities including a $100M ATM facility. This follows a prior S-3 filing 3 days earlier and comes amid an unresolved FDA partial clinical hold on its lead DM1 candidate, with Q1 2026 cash of $132.3M sufficient into 2H 2027. The effectiveness creates immediate dilution overhang for existing shareholders.
Key Facts
- S-3 shelf registration became effective on May 21, 2026
- Shelf covers up to $400M in securities including a $100M ATM facility
- Prior S-3 filed May 19, 2026 replaced an ATM with $88.5M remaining capacity
- Q1 2026 net loss of $17.8M; cash of $132.3M sufficient into 2H 2027
- Unresolved FDA partial clinical hold on lead DM1 candidate
- Massive increase in authorized ATM capacity signals expected need for significant additional capital
Financial Impact
Up to $400M in potential dilution from shelf securities, with $100M ATM facility representing ~93% of current $107M market cap
Risk Factors
- Immediate dilution overhang from $100M ATM facility
- Unresolved FDA partial clinical hold on lead DM1 candidate
- Cash runway only into 2H 2027 without additional capital
- Historical model calls on PEPG have underperformed significantly (avg -61.66% at T+20)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001734 |
| Document: 9999999995-26-001734-index.html | 9999999995-26-001734 |
| Document: 9999999995-26-001734.txt | 9999999995-26-001734 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $2.41 $3.18 | ▲ +31.95% | ▲ +31.35% | $2.27 (−6.02%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.51 $2.30 | ▲ +52.32% | ▲ +50.43% | $2.27 (+50.00%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.51 $2.30 | ▲ +52.32% | ▲ +50.43% | $2.27 (+50.00%) |
May 22, 2026 19w ago | EFFECT | $1.51 $1.90 | ▼ −25.83% | ▼ −27.24% | $2.27 (−50.00%) |
May 19, 2026 19w ago | S-3 | $1.38 $1.70 | ▼ −23.19% | ▼ −22.20% | $2.27 (−64.13%) |
May 12, 2026 20w ago | 8-K | $1.78 $1.51 | ▼ −15.17% | ▼ −14.56% | $2.27 (+27.25%) |
Mar 4, 2026 30w ago | 8-K | $5.51 $1.73 | ▼ −68.57% | ▼ −64.79% | $2.27 (−58.86%) |
Mar 4, 2026 30w ago | Insider Cluster | $6.76 $1.74 | ▼ −74.26% | ▼ −69.84% | $2.27 (−66.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access